Iris Alroy, Ph.D. has 25 years of experience in drug discovery, preclinical and early clinical development. Dr. Alroy has served as CSO of Anima since 2015, supervising drug discovery and pipeline development in the emerging field of mRNA translation regulation. Prior to Anima, she acted as VP of Discovery at Proteologics and Pharmos Corp. and CEO of several startup biotech companies, including Fusimab, Ltd. and ProMining Therapeutics Ltd.
